OncoMatch/Clinical Trials/NCT06669117
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Is NCT06669117 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies VERT-002 for solid tumor.
Treatment: VERT-002 — The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: MET exon 14 mutation
METex14 mutation
Required: MET kinase domain activating mutation
MET kinase domain activating gene mutations (e.g. H1094L/R/Y, D1228H/N/V, Y1230A/C/D/H)
Required: MET amplification
MET amplification
Required: MET de novo amplification
de novo MET amplification
Disease stage
Required: Stage III, IIIB, IIIC, IV (AJCC 8th edition)
Metastatic disease required
locally advanced or metastatic NSCLC Stage IIIB/C or IV (American Joint Commission on Cancer [AJCC] 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: MET inhibitor
Exception: MET TKI within 7 days prior to the first dose of VERT-002
MET TKI within 7 days prior to the first dose of VERT-002
Cannot have received: systemic anticancer therapy
Exception: within 28 days or 5 half-lives of the anticancer therapy whichever is the shortest, but with a minimum of 14 days interval, prior to the first dose of VERT-002
Any other systemic anticancer therapy within 28 days or 5 half-lives of the anticancer therapy whichever is the shortest, but with a minimum of 14 days interval, prior to the first dose of VERT-002 (C1D1)
Cannot have received: radiation therapy
Exception: to a large field or including a vital organ (including whole brain radiotherapy or stereotactic radiosurgery to brain) within 14 days prior to the first dose of VERT-002
Radiotherapy to a large field or including a vital organ (including whole brain radiotherapy or stereotactic radiosurgery to brain) within 14 days prior to the first dose of VERT-002 (C1D1)
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
adequate cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Georgetown Lombardi Comprehensive Cancer Center · Washington D.C., District of Columbia
- Gabrail Cancer Research Center · Canton, Ohio
- Sarah Cannon Research Institute Oncology Partners · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06669117 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MET inhibitor, systemic anticancer therapy, radiation therapy disqualifies patients from enrollment.
Does this trial require MET?
Yes, MET exon 14 mutation is a required biomarker for enrollment.
Does this trial require MET?
Yes, MET kinase domain activating mutation is a required biomarker for enrollment.
Does this trial require MET?
Yes, MET amplification is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IIIB or IIIC or IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify